| P50 | author | Xavier Pivot | Q66829173 |
| | Thomas Bachelot | Q89504757 |
| | Julie Henriques | Q116878125 |
| P2093 | author name string | Marc Espié | |
| | Marc Debled | |
| | Pierre Fumoleau | |
| | Alain Lortholary | |
| | David Khayat | |
| | Christelle Jouannaud | |
| | Gilles Romieu | |
| | Iris Pauporté | |
| | Jean-Philippe Jacquin | |
| | Jean-Yves Pierga | |
| | Maria Rios | |
| | Pierre Kerbrat | |
| | Sophie Paget-Bailly | |
| | Laurence Venat-Bouvet | |
| | Laurent Cany | |
| | Daniel Serin | |
| | Laetitia Gambotti | |
| | Sophie Abadie-Lacourtoisie | |
| | Celine Faure-Mercier | |
| | Jean Marie Grouin | |
| | PHARE trial investigators | |
| | Stéphanie Catala | |
| P2860 | cites work | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 |
| | Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | Q33964848 |
| | Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. | Q34484185 |
| | Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 |
| | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial | Q38953228 |
| | CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial | Q39358281 |
| | Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. | Q41596197 |
| | 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. | Q43784378 |
| | The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt | Q44951448 |
| | Regression analysis of restricted mean survival time based on pseudo-observations | Q45250683 |
| | 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial | Q47973074 |
| | Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive | Q49662502 |
| | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 |
| | Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). | Q53521179 |
| | Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial | Q57110471 |
| | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer | Q62022868 |
| | Adjuvant chemotherapy for local relapse breast cancer | Q87120961 |
| | Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial | Q88933702 |
| | Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡ | Q91468046 |
| P433 | issue | 10191 | |
| P921 | main subject | trastuzumab | Q412616 |
| | phase III clinical trial | Q42824827 |
| P304 | page(s) | 2591-2598 | |
| P577 | publication date | 2019-06-06 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial | |
| P478 | volume | 393 | |